Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

655 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V. Mahaffey KW, et al. Among authors: de zeeuw d. Circulation. 2019 Aug 27;140(9):739-750. doi: 10.1161/CIRCULATIONAHA.119.042007. Epub 2019 Jul 11. Circulation. 2019. PMID: 31291786 Free PMC article. Clinical Trial.
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Asselbergs FW, et al. Among authors: de jong pe, de zeeuw d. Circulation. 2004 Nov 2;110(18):2809-16. doi: 10.1161/01.CIR.0000146378.65439.7A. Epub 2004 Oct 18. Circulation. 2004. PMID: 15492322 Clinical Trial.
Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Declaration.
Dirks JH, de Zeeuw D, Agarwal SK, Atkins RC, Correa-Rotter R, D'Amico G, Bennett PH, El Nahas M, Valdes RH, Kaseje D, Katz IJ, Naicker S, Rodriguez-Iturbe B, Schieppati A, Shaheen F, Sitthi-Amorn C, Solez K, Viberti G, Remuzzi G, Weening JJ; International Society of Nephrology Commission for the Global Advancement of Nephrology Study Group 2004. Dirks JH, et al. Among authors: d amico g, de zeeuw d. Kidney Int Suppl. 2005 Sep;(98):S1-6. doi: 10.1111/j.1523-1755.2005.09800.x. Kidney Int Suppl. 2005. PMID: 16108963 Free article.
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Hillege HL, et al. Among authors: de zeeuw d. Circulation. 2006 Feb 7;113(5):671-8. doi: 10.1161/CIRCULATIONAHA.105.580506. Circulation. 2006. PMID: 16461840
Renoprotective effects of renin-angiotensin-system inhibitors.
de Zeeuw D, Lewis EJ, Remuzzi G, Brenner BM, Cooper ME. de Zeeuw D, et al. Lancet. 2006 Mar 18;367(9514):899-900; author reply 900-2. doi: 10.1016/S0140-6736(06)68374-8. Lancet. 2006. PMID: 16546533 No abstract available.
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.
Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlöf B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K, de Zeeuw D. Eijkelkamp WB, et al. Among authors: de zeeuw d. J Hypertens. 2007 Apr;25(4):871-6. doi: 10.1097/HJH.0b013e328014953c. J Hypertens. 2007. PMID: 17351381
655 results